Board summary
Key figures
50,158
Registered population
55.3% aged 18–64
27.6%
Aged 65+
ICB 19.9% · England 17.9%
8.3%
Ethnic minority (non-White)
4.5% Asian · England 9.6%
7.8%
In IMD quintile 1
ICB 17.1% · England 21.0%
~3,324
Core20 residents (est.)
Resident basis; registered basis ~4,116 · see page 3
9,439
Hypertension register
+3.14% in 3 yrs · England +5.60%
508
SMI register
36% of Folkestone and Hythe's
1,117
COPD register
Reviews +4.79% in 3 yrs
Forecast to 2030
10,384
Hypertension patients, 2030
+945 on today
63.1%
QRISK ≥20% on statins, 2030
+3.00pp over 3 yrs
7.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy and diabetes statins lag.
Lipid-lowering therapy for QRISK >= 20% is 56.6% (England 63.6%), while statin treatment in diabetes fell 1.7% to 69.2% (England +2.1%, 73.2%).
Hypertension control and COPD reviews exceed England.
Hypertension treatment to target is 71.7% (England 70.3%, ICB 67.7%), and annual COPD reviews rose +4.8% to 77.0% (England +2.8%, 76.4%).
Population, age and ethnicity
With 27.6% aged 65+, an older population may increase PCN complex care demand
Of 50,158 registered patients, 27.6% (13,842) are aged 65+, exceeding Folkestone and Hythe (25.7%), the ICB (19.9%) and England (17.9%). Working-age patients (18–64) represent 55.3% (LAD 56.9%, ICB 59.5%, England 62.7%) and children (0–17) 17.1% (LAD 17.4%, ICB 20.7%, England 19.6%). Based on resident Census estimates rather than registered ethnicity, White residents represent 91.7% across the PCN (LAD 92.6%, ICB 88.6%, England 81.1%), and the PCN ethnic minority share is 8.3%. Asian / Asian British residents comprise 4.5% across the PCN. At White House Surgery, Asian / Asian British residents account for 10.1%.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Folkestone and Hythe local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Folkestone & Hythe LA) | 1,699 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Folkestone & Hythe LA) | 856 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Folkestone & Hythe LA) | 16.0 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 7.8% overall but reaches 77.6% at Harbour Medical Practice
The PCN Core20 share is 7.8%, below Folkestone and Hythe (21.7%), the ICB (17.1%) and England (21.0%). However, deprivation is sharply polarised across practices: Harbour Medical Practice has a 77.6% Core20 share (2,580 estimated patients), whereas White House Surgery has 0.0%. Practice-level registered estimates sum to 4,116 patients, whereas resident decile 1 and 2 counts total 3,324. This discrepancy between registered and resident bases requires local reconciliation to avoid misdirecting neighbourhood outreach capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
508
SMI register
1.00% recorded prevalence
321
Learning disability register
0.63% recorded prevalence
46
Care homes, 984 beds
In the PCN catchment
10.2%
Provide unpaid care
Folkestone and Hythe, Census 2021
The PCN records 508 severe mental illness patients (1.0%; LAD 1.2%, ICB 0.9%, England 1.0%) and 321 with learning disabilities (0.6%; LAD 0.9%, ICB 0.6%, England 0.6%), with 46 catchment care homes (984 beds). Borough data shows 21 rough sleepers and a 10.2% carer rate.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.0% (508 patients). On the SMI register, annual blood pressure checks reached 76.8% (England 83.4%) and BMI recording reached 76.5% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,439
Hypertension register
+3.14%
Register growth, 3 yrs
Folkestone and Hythe +5.18% · England +5.60%
−0.09pp
BP control, under 80
≤140/90 · +2.14pp aged 80+
+945
More patients by 2030
Forecast 10,384 (19.79%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.6% (9,439 patients), above England (15.2%) and NHS Kent and Medway ICB (16.2%), with practice prevalence ranging from 13.6% at White House Surgery to 23.0% at Church Road. Although 71.7% of patients are treated to target (England 70.3%), three-year change in blood pressure control for patients under 80 fell 0.1% over 2023 to 2025 (England +3.2%; Folkestone and Hythe +6.3%).
Lipids and statins
Recorded lipid-lowering therapy for QRISK ≥ 20% is 56.6%, trailing England (63.6%) and NHS Kent and Medway ICB (61.4%), while statin treatment in diabetes aged 40+ without CVD fell 1.7% over 2023 to 2025 to 69.2% (England +2.1%, 73.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 97,437 | £2.20 | £1.90 | £1.86 | £214,361 |
| Cardiovascular (all), 2025 | 134,620 | £4.28 | £3.57 | £3.33 | £576,174 |
In 2026, lipid-regulating drugs averaged £2.20 per item across 97,437 items, exceeding England (£1.86), NHS Kent and Medway ICB (£1.90), and Folkestone and Hythe (£2.17), spending £33,129 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.34%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.79%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.2% (1,117 patients; England 1.9%) with 77.0% reviewed annually (England 76.4%), up +4.8% over 2023 to 2025 (England +2.8%). Recorded asthma prevalence is 6.6% (3,169 patients; England 6.6%), but annual reviews fell 2.3% over 2023 to 2025 to 63.2% (England +4.4%, 65.7%), leaving an unreviewed scale indicator of 1,165 patients. Second-hand smoke status recording in asthma patients aged 6-19 is 73.8% (England 78.8%).
Cancer register and children's immunisation
Cancer register prevalence is 5.8% (2,952 patients; England 3.8%). In Q1 2025/26 childhood immunisations, age-5 MMR dose 1 reached 95.7% but dose 2 is 90.4% (target 95.0%), a 5.3 pp dose difference. At White House Surgery, dose 2 is 81.1% against 94.6% for dose 1 (a 13.5 pp difference). Age-5 4-in-1 booster coverage is 86.1%, 8.9 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of staged ICB cancers were diagnosed at stage 1 or 2 (England 55.3%; 75.0% national ambition, 19.4 pp below standard), requiring 1,627 extra early-stage cases to reach target. ICB known-stage coverage was 63.6% (8,384 of 13,189 cancers; England 67.0%), reflecting wider-system pathways rather than PCN performance. PCN cancer prevalence is 5.8% (2,952 patients; England 3.8%). Breast screening coverage is 71.2% (England 69.9%; three-year change +10.9%, England +8.4%). Cervical screening in women aged 25 to 49 fell 3.6% over 2023 to 2025 (England -1.0%) to 69.6% (England 66.8%), reaching 63.1% at Sun Lane and 65.6% at White House Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), East Kent Hospitals University NHS Foundation Trust achieved 70.0% on the 62-day referral to treatment standard (15.0 pp below the 85.0% standard), compared with 87.4% at Maidstone and Tunbridge Wells NHS Trust, 67.0% at East Sussex Healthcare NHS Trust, 75.9% across NHS Kent and Medway Integrated Care Board, and 71.2% in England. On the 28-day faster diagnosis standard, East Kent Hospitals achieved 71.3% (3.7 pp below the 75.0% standard; NHS Kent and Medway Integrated Care Board 76.8%, England 79.3%). These acute figures describe system pressures rather than PCN performance.
| Pathways within standard (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 84.20 | 81.78 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 98.19 | 98.35 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 67.04 | 87.43 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 47.58 | 6.48 | 0.92 | 21.40 |
| CT | 37.45 | 0.48 | 0.51 | 9.92 |
| Echocardiography | 14.17 | 21.94 | 2.57 | 28.48 |
| Colonoscopy | 9.58 | 0.74 | 19.80 | 30.83 |
| Gastroscopy | 22.16 | 0.31 | 24.03 | 29.02 |
| All 15 DM01 tests | 48.38 | 5.27 | 6.42 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In the Community Services Dataset for Jun 2026 (provisional), adults aged 65 and over accounted for 65.8% of community contacts among Folkestone and Hythe borough residents (138,250 of 210,170 contacts). Provider-level and PCN-level breakdowns were not captured. These borough-level contacts reflect wider community service use rather than PCN activity.
Practice variation and patient experience
Practice variation and patient experience
Across practices in 2025/26, QOF vaccination and immunisation achievement varied by 53.7 pp, from 26.9% at White House Surgery to 80.6% at New Lyminge Surgery (England 55.2%). Overall QOF achievement was 75.3% at White House Surgery (England 92.5%), while Oaklands Health Centre reached 91.6%. Variation across practices remains unverified locally.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Church Road | 125 | 0.0 | 94.8% | 77.7% | 95.6% |
| New Lyminge | 122 | 0.0 | 55.8% | 62.7% | 75.3% |
| Hawkinge And Elham | 97 | 0.0 | 50.1% | 67.6% | 74.0% |
| Sun Lane | 110 | 7.5 | 56.1% | 73.8% | 72.0% |
| Oaklands | 124 | 9.2 | 49.2% | 61.4% | 71.9% |
| White House | 111 | 0.0 | 28.3% | 50.4% | 64.9% |
| Harbour Medical | 102 | 77.6 | 45.5% | 61.3% | 48.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked measures trailed England's three-year change, led by reviews
Sixteen of 25 tracked measures trailed England over three years. The widest relative lags were in annual asthma reviews, down 2.3% (England +4.4%), statin treatment in diabetes without CVD, down 1.7% (England +2.1%), and heart failure reviews, up 5.3% (England +8.7%). Smoking cessation support fell 2.9 pp (England +0.1 pp). Conversely, severe mental illness checks improved: BMI recording rose 11.0 pp (England +5.1 pp) and alcohol recording rose 8.2 pp (England +5.4 pp). This divergence could reflect clinical recall prioritisation, unverified without local audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Diabetes statin (no CVD)
Heart failure reviews
BP control, under 80
Hypertension treated to target
BMI record (SMI)
Alcohol record (psychosis)
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Folkestone and Hythe | Asset | PCN | Folkestone and Hythe |
|---|---|---|---|---|---|
| Care homes (catchment) | 46 (984 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | 5 | 8 | Places of worship | 60 | 78 |
| Libraries | 6 | 8 | Food banks (VCS) | n/a | 1 |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | 1 | 1 | Primary schools (LA maintained) | 19 | 21 |
| Primary academies | 11 | 15 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured annual asthma review recall
Annual asthma reviews fell 2.3% over 2023 to 2025 to 63.2% (England +4.4%, 65.7%; Folkestone and Hythe 59.1%; ICB 60.4%), a scale indicator of 1,165 unreviewed patients of 3,169. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Two-track Core20 neighbourhood outreach
Average IMD decile is 5.5 and Core20 share is 7.8% (England 21.0%; Folkestone and Hythe 21.7%), but Harbour Medical Practice reaches 77.6% (2,580 estimated patients) with 48.4% good experience (England 76.7%). Moderate effort to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Option 3
Pharmacist-led lipid and statin review
Lipid-lowering therapy for QRISK ≥ 20% is 56.6% (England 63.6%; ICB 61.4%), while statins in diabetes (40+ without CVD) fell 1.7% to 69.2% (England +2.1%, 73.2%). For discussion, pharmacists could recall untreated high-risk and diabetic cohorts alongside a formulary review (£33,129 more than England's unit cost across 97,437 items). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted language and access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Reconcile Core20 patient outreach lists (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Under-eighty blood pressure review audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Two-track Core20 neighbourhood outreach (p12) | Average IMD decile · Core20 cohort (IMD quintile 1) · GPPS good overall experience of the practice | Core20PLUS5 · 10YHP equity test · 10YHP, hospital to community | PCN & Practice |
| Option 3 · Pharmacist-led lipid and statin review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
